NEW YORK, Jan. 14, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Alcobra Ltd. ("Alcobra" or the "Company") (Nasdaq:ADHD) securities between March 28, 2014 and November 14, 2014.
Click here to learn about the case: http://docs.wongesq.com/ADHD-Info-Request-Form-565. There is no cost or obligation to you.
The complaint alleges that Alcobra failed to disclose during the Class Period that, despite statements to the contrary, its drug MDX did not show a statistical benefit over placebo unless certain patients were removed from the Company's analysis of the Phase III study such that the Company presented its analyses inconsistent with and outside the original protocols.
On October 22, 2014, Alcobra announced that the MDX Phase III study, in fact, did not demonstrate a statistically significant improvement in patient symptoms. Then on November 17, 2014, the Company announced that it would meet with the FDA to launch a second adult Phase III study next year.
If you suffered a loss in Alcobra you have until January 20, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/ADHD-Info-Request-Form-565.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
